Eli Lilly Lifts Outlook After Strong Quarter

Eli Lilly posted third-quarter results that topped expectations and raised its outlook, sending shares up 5% premarket. Adjusted EPS reached $7.02 on revenue of $17.60 billion, beating estimates. The company now targets fiscal 2025 revenue of $63–$63.5 billion and full-year adjusted profit of $23–$23.70 per share. Demand for GLP-1 drugs powered the quarter: Mounjaro generated $6.52 billion, up 109% and above forecasts, while Zepbound brought in $3.57 billion, up 184% and slightly ahead of estimates. The strong showing comes as Lilly seeks to maintain its edge over Novo Nordisk in the booming obesity and diabetes market.